(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

ONIVYDE(R) Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas who have Progressed Following Gemcitabine based Therapy

July 25th, 2016

The positive opinion is based on a pivotal Phase 3 study showing that ONIVYDE combined with chemotherapy significantly increased overall survival (OS) in patients with metastatic pancreatic cancer after previous gemcitabine based therapy Zug, Swit. Read more

Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016

July 24th, 2016

Results Feature Favorable Safety, Maximum Tolerated Dose, Positive Dose Response as well as Positive Unexpected Therapeutic Response Events NEW YORK, NY / CRWE PRESS RELEASE / July 24, 2016 – Anavex Life Sciences Corp. (“Anavex” . Read more

SkyWest Airlines and ExpressJet Airlines Extend Heavy Maintenance Agreements Covering Bombardier CRJ Series Regional Jets

July 23rd, 2016

Montréal, Québec / CRWE PRESS RELEASE / July 22, 2016 - Bombardier Commercial Aircraft announced today that Bombardier Services Corporation has extended Heavy Maintenance Agreements with SkyWest, Inc. (NASDAQ: SKYW) carriers SkyWest Air. Read more

Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)

July 21st, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / July 21, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced updated results from the Phase III clinical trial of Puma's investigational drug PB272 (neratinib) for t. Read more

Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

July 21st, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / July 21, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candida. Read more

CP reaches agreement with future CEO, Keith Creel; retains services of E. Hunter Harrison beyond retirement

July 21st, 2016

Calgary, AB / CRWE PRESS RELEASE / July 20, 2016 - Canadian Pacific Railway Limited (TSX: CP) (NYSE: CP) today announced that CP's Board of Directors has reached an agreement with CP's next chief executive officer, Keith Creel. Currently pres. Read more

Joy Global Announces Agreement to Be Acquired by Komatsu in $3.7 Billion All-Cash Transaction

July 21st, 2016

Delivers substantial all-cash premium to Joy Global stockholders Komatsu committed to long-term growth of Joy Global, which will operate as a separate subsidiary of Komatsu Milwaukee, WI / CRWE PRESS RELEASE / July 21, 2016 - Joy Global Inc. (N. Read more

Joy Global to sell Texas steel plate mill to Nucor Corporation

July 20th, 2016

MILWAUKEE, WI / CRWE PRESS RELEASE / July 20, 2016 - Joy Global (NYSE: JOY) has agreed to sell its steel plate mill in Longview, Texas, to Nucor Corporation (NYSE: NUE), the largest steel producer in the United States, for approximately $29 million. . Read more

Ballard Signs Follow-On Technology Solutions Agreement With Leading Global Automotive OEM

July 20th, 2016

VANCOUVER, CANADA / CRWE PRESS RELEASE / July 20, 2016 – Ballard Power Systems (NASDAQ: BLDP; TSX: BLD) today announced that it has signed a follow-on Technology Solutions contract with an unnamed leading global automotive OEM. Under the c. Read more

Transgenomic Licenses Commercial Rights to Its Long QT Syndrome DNA Testing Portfolio to LabCorp

July 20th, 2016

LabCorp’s DNA Testing for Long QT Syndrome, a Congenital Heart Rhythm Disorder Associated with Potentially Lethal Arrhythmias, is Enhanced by TBIO’s Intellectual Property OMAHA, NE / CRWE PRESS RELEASE / July 20, 2016 - Transgenom. Read more